James Matthew Robins, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 62 | 2018 | 4748 | 4.460 |
Why?
|
| Causality | 21 | 2017 | 970 | 3.370 |
Why?
|
| Data Interpretation, Statistical | 32 | 2018 | 2670 | 3.260 |
Why?
|
| Epidemiologic Methods | 27 | 2013 | 1424 | 2.410 |
Why?
|
| Probability | 21 | 2012 | 2424 | 1.410 |
Why?
|
| Biometry | 13 | 2010 | 508 | 1.320 |
Why?
|
| Epidemiologic Research Design | 5 | 2017 | 352 | 1.300 |
Why?
|
| Randomized Controlled Trials as Topic | 21 | 2016 | 8189 | 1.240 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2016 | 1196 | 1.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 10 | 2015 | 1901 | 1.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 11 | 2011 | 2188 | 1.030 |
Why?
|
| Research Design | 14 | 2017 | 5240 | 1.020 |
Why?
|
| Zidovudine | 7 | 2004 | 626 | 1.010 |
Why?
|
| Epidemiologic Studies | 4 | 2010 | 609 | 0.880 |
Why?
|
| Patient Dropouts | 3 | 2012 | 413 | 0.850 |
Why?
|
| Intention to Treat Analysis | 2 | 2017 | 366 | 0.840 |
Why?
|
| Selection Bias | 7 | 2015 | 315 | 0.820 |
Why?
|
| CD4 Lymphocyte Count | 18 | 2017 | 2533 | 0.780 |
Why?
|
| Likelihood Functions | 5 | 2018 | 962 | 0.770 |
Why?
|
| Anti-HIV Agents | 14 | 2017 | 3716 | 0.750 |
Why?
|
| Sphenoid Sinus | 1 | 2017 | 99 | 0.750 |
Why?
|
| Regression Analysis | 11 | 2018 | 6642 | 0.710 |
Why?
|
| Progestins | 2 | 2016 | 264 | 0.710 |
Why?
|
| Bayes Theorem | 8 | 2017 | 1451 | 0.710 |
Why?
|
| Computer Graphics | 2 | 2007 | 343 | 0.670 |
Why?
|
| Clinical Trials as Topic | 7 | 2012 | 7480 | 0.670 |
Why?
|
| HIV Infections | 21 | 2017 | 13539 | 0.670 |
Why?
|
| Mortality | 4 | 2017 | 2355 | 0.650 |
Why?
|
| Personnel, Hospital | 1 | 2015 | 238 | 0.590 |
Why?
|
| Comparative Effectiveness Research | 3 | 2016 | 628 | 0.590 |
Why?
|
| Survival Analysis | 13 | 2016 | 10100 | 0.580 |
Why?
|
| Observation | 4 | 2017 | 314 | 0.560 |
Why?
|
| Disease Outbreaks | 5 | 2008 | 1488 | 0.520 |
Why?
|
| Viral Load | 9 | 2017 | 2704 | 0.520 |
Why?
|
| Clinical Protocols | 1 | 2017 | 1365 | 0.500 |
Why?
|
| Communicable Diseases | 2 | 2008 | 669 | 0.490 |
Why?
|
| Endoscopy | 2 | 2017 | 1522 | 0.460 |
Why?
|
| Pituitary Neoplasms | 1 | 2017 | 1146 | 0.450 |
Why?
|
| Vietnam Conflict | 1 | 2010 | 100 | 0.450 |
Why?
|
| Statistics as Topic | 12 | 2016 | 2545 | 0.450 |
Why?
|
| Heroin Dependence | 1 | 2010 | 183 | 0.430 |
Why?
|
| Treatment Refusal | 4 | 2006 | 427 | 0.420 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2012 | 501 | 0.400 |
Why?
|
| HIV-1 | 9 | 2017 | 6343 | 0.390 |
Why?
|
| Vaccines | 2 | 2012 | 457 | 0.380 |
Why?
|
| Humans | 131 | 2018 | 602421 | 0.370 |
Why?
|
| Adenoma | 1 | 2017 | 2005 | 0.370 |
Why?
|
| Longitudinal Studies | 16 | 2016 | 11563 | 0.370 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 2022 | 0.360 |
Why?
|
| Anti-Retroviral Agents | 3 | 2015 | 1376 | 0.360 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2000 | 239 | 0.330 |
Why?
|
| RNA, Viral | 2 | 2016 | 2523 | 0.310 |
Why?
|
| Case-Control Studies | 11 | 2004 | 19967 | 0.300 |
Why?
|
| Dementia | 1 | 2015 | 1815 | 0.300 |
Why?
|
| Computer Simulation | 10 | 2018 | 5757 | 0.290 |
Why?
|
| Pharmacoepidemiology | 1 | 2006 | 276 | 0.280 |
Why?
|
| Air Pollution | 1 | 2013 | 1464 | 0.280 |
Why?
|
| Weight Gain | 2 | 2016 | 2040 | 0.280 |
Why?
|
| Benzoxazines | 2 | 2016 | 279 | 0.280 |
Why?
|
| Linear Models | 3 | 2007 | 5979 | 0.270 |
Why?
|
| Particulate Matter | 1 | 2013 | 1703 | 0.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 2723 | 0.270 |
Why?
|
| Proportional Hazards Models | 12 | 2011 | 11540 | 0.270 |
Why?
|
| Air Pollutants | 2 | 2013 | 2144 | 0.260 |
Why?
|
| Mathematics | 8 | 2009 | 771 | 0.260 |
Why?
|
| Epidemiology | 4 | 1989 | 301 | 0.250 |
Why?
|
| Stochastic Processes | 5 | 2008 | 339 | 0.240 |
Why?
|
| Stroke | 2 | 2016 | 7902 | 0.240 |
Why?
|
| Multicenter Studies as Topic | 4 | 2007 | 1308 | 0.230 |
Why?
|
| Risk | 12 | 1999 | 9610 | 0.230 |
Why?
|
| Comorbidity | 5 | 2013 | 9594 | 0.230 |
Why?
|
| Environmental Exposure | 6 | 2004 | 3639 | 0.230 |
Why?
|
| Decision Making | 3 | 2017 | 3666 | 0.220 |
Why?
|
| HIV Seropositivity | 2 | 2016 | 887 | 0.210 |
Why?
|
| Statistics, Nonparametric | 5 | 2006 | 3015 | 0.200 |
Why?
|
| Breast Neoplasms | 7 | 2016 | 17695 | 0.200 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 1306 | 0.200 |
Why?
|
| Models, Theoretical | 5 | 2017 | 3405 | 0.200 |
Why?
|
| Educational Status | 1 | 2005 | 2199 | 0.190 |
Why?
|
| Therapeutic Equivalency | 1 | 1998 | 159 | 0.190 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 5261 | 0.190 |
Why?
|
| Influenza, Human | 4 | 2010 | 1073 | 0.190 |
Why?
|
| Genetics | 1 | 1998 | 119 | 0.190 |
Why?
|
| Coronary Disease | 4 | 2016 | 6180 | 0.190 |
Why?
|
| Models, Genetic | 3 | 2007 | 3523 | 0.190 |
Why?
|
| Logistic Models | 6 | 2013 | 13309 | 0.190 |
Why?
|
| Medroxyprogesterone | 1 | 2016 | 33 | 0.180 |
Why?
|
| AIDS-Related Complex | 1 | 2016 | 112 | 0.180 |
Why?
|
| Occupational Diseases | 7 | 1989 | 1439 | 0.180 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2018 | 176 | 0.180 |
Why?
|
| Linkage Disequilibrium | 1 | 2001 | 1895 | 0.180 |
Why?
|
| Critical Illness | 1 | 2007 | 1753 | 0.180 |
Why?
|
| Time Factors | 18 | 2018 | 40261 | 0.170 |
Why?
|
| Female | 42 | 2018 | 337686 | 0.170 |
Why?
|
| Learning Curve | 1 | 2017 | 172 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2000 | 693 | 0.170 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 336 | 0.170 |
Why?
|
| Evaluation Studies as Topic | 2 | 2012 | 1867 | 0.160 |
Why?
|
| Education, Nursing | 1 | 2015 | 73 | 0.160 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 1971 | 0.160 |
Why?
|
| Models, Biological | 4 | 2007 | 10185 | 0.160 |
Why?
|
| Forced Expiratory Volume | 3 | 1992 | 1632 | 0.160 |
Why?
|
| Drug Therapy, Combination | 5 | 2016 | 6303 | 0.160 |
Why?
|
| Treatment Outcome | 17 | 2018 | 53963 | 0.150 |
Why?
|
| Algorithms | 9 | 2010 | 12337 | 0.150 |
Why?
|
| Drug Administration Schedule | 5 | 2012 | 5039 | 0.150 |
Why?
|
| Ecology | 1 | 1994 | 97 | 0.150 |
Why?
|
| Smoking Cessation | 2 | 2016 | 1725 | 0.150 |
Why?
|
| Nonlinear Dynamics | 1 | 1997 | 499 | 0.150 |
Why?
|
| Hydrocephalus | 1 | 2018 | 581 | 0.140 |
Why?
|
| Cardiovascular Diseases | 4 | 2008 | 11773 | 0.140 |
Why?
|
| Thrombophlebitis | 1 | 1993 | 319 | 0.140 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2016 | 573 | 0.140 |
Why?
|
| Cohort Studies | 13 | 2016 | 34117 | 0.140 |
Why?
|
| United States | 15 | 2016 | 55949 | 0.130 |
Why?
|
| Developed Countries | 4 | 2017 | 356 | 0.130 |
Why?
|
| Male | 41 | 2018 | 319954 | 0.130 |
Why?
|
| Dermoid Cyst | 1 | 2013 | 96 | 0.130 |
Why?
|
| Risk Factors | 19 | 2018 | 61976 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2005 | 4213 | 0.130 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 5013 | 0.130 |
Why?
|
| Europe | 5 | 2017 | 2934 | 0.130 |
Why?
|
| Brain Ischemia | 1 | 2005 | 2958 | 0.130 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2012 | 210 | 0.130 |
Why?
|
| Cause of Death | 6 | 2017 | 3163 | 0.130 |
Why?
|
| Health Status | 1 | 2005 | 3702 | 0.120 |
Why?
|
| Job Satisfaction | 1 | 2015 | 483 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2017 | 1776 | 0.120 |
Why?
|
| Nevirapine | 1 | 2012 | 262 | 0.120 |
Why?
|
| Postmenopause | 2 | 2016 | 2279 | 0.120 |
Why?
|
| Scalp | 1 | 2013 | 279 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2017 | 847 | 0.120 |
Why?
|
| Nose Neoplasms | 1 | 2013 | 239 | 0.120 |
Why?
|
| Confidence Intervals | 3 | 2010 | 3085 | 0.120 |
Why?
|
| Oseltamivir | 1 | 2010 | 59 | 0.120 |
Why?
|
| Middle Aged | 29 | 2018 | 195518 | 0.120 |
Why?
|
| Family Characteristics | 2 | 2012 | 826 | 0.110 |
Why?
|
| Cross-Over Studies | 1 | 1995 | 1825 | 0.110 |
Why?
|
| Cognition Disorders | 1 | 2005 | 4010 | 0.110 |
Why?
|
| Adult | 34 | 2018 | 191224 | 0.110 |
Why?
|
| Nose | 1 | 2013 | 415 | 0.110 |
Why?
|
| Fishes | 1 | 2013 | 575 | 0.110 |
Why?
|
| Mathematical Computing | 2 | 2007 | 159 | 0.110 |
Why?
|
| Propensity Score | 1 | 2016 | 1433 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 4037 | 0.110 |
Why?
|
| Obesity | 3 | 2018 | 10418 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2017 | 2657 | 0.100 |
Why?
|
| Smoking | 11 | 2013 | 8563 | 0.100 |
Why?
|
| Epistasis, Genetic | 1 | 2010 | 374 | 0.100 |
Why?
|
| Mass Screening | 1 | 2004 | 4569 | 0.100 |
Why?
|
| Chicago | 1 | 2007 | 196 | 0.090 |
Why?
|
| Population Density | 1 | 2007 | 144 | 0.090 |
Why?
|
| Temperature | 1 | 2013 | 2026 | 0.090 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2008 | 249 | 0.090 |
Why?
|
| Weight Loss | 2 | 2016 | 2025 | 0.090 |
Why?
|
| Life Expectancy | 2 | 1991 | 1091 | 0.090 |
Why?
|
| Exercise | 3 | 2018 | 4287 | 0.090 |
Why?
|
| Data Collection | 3 | 2001 | 3238 | 0.090 |
Why?
|
| Disease Transmission, Infectious | 2 | 2010 | 412 | 0.090 |
Why?
|
| Mining | 1 | 1987 | 89 | 0.090 |
Why?
|
| Random Allocation | 6 | 1990 | 2537 | 0.090 |
Why?
|
| Heparin | 1 | 1993 | 1541 | 0.090 |
Why?
|
| Sensitivity and Specificity | 5 | 2004 | 14684 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 409 | 0.090 |
Why?
|
| Prospective Studies | 11 | 2017 | 42794 | 0.090 |
Why?
|
| Premature Birth | 1 | 2014 | 935 | 0.090 |
Why?
|
| Diet | 3 | 2018 | 6404 | 0.080 |
Why?
|
| Disease | 2 | 2004 | 659 | 0.080 |
Why?
|
| Bulimia | 1 | 2007 | 376 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2010 | 10655 | 0.080 |
Why?
|
| Urban Population | 1 | 2013 | 1964 | 0.080 |
Why?
|
| Odds Ratio | 5 | 2010 | 9788 | 0.080 |
Why?
|
| Reproducibility of Results | 4 | 2012 | 17820 | 0.080 |
Why?
|
| Estrogens | 2 | 2010 | 1400 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2016 | 11259 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2012 | 2771 | 0.080 |
Why?
|
| Sample Size | 1 | 2007 | 689 | 0.080 |
Why?
|
| Survival Rate | 4 | 2013 | 12345 | 0.080 |
Why?
|
| Environment | 1 | 2010 | 1029 | 0.080 |
Why?
|
| Homosexuality, Male | 2 | 2004 | 798 | 0.080 |
Why?
|
| Cyanates | 1 | 1983 | 30 | 0.080 |
Why?
|
| Length of Stay | 1 | 2017 | 5435 | 0.070 |
Why?
|
| Monte Carlo Method | 3 | 2017 | 1251 | 0.070 |
Why?
|
| Toluene 2,4-Diisocyanate | 1 | 1983 | 15 | 0.070 |
Why?
|
| Child Development | 2 | 2006 | 2078 | 0.070 |
Why?
|
| Didanosine | 1 | 2003 | 154 | 0.070 |
Why?
|
| Germany | 1 | 2005 | 772 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2001 | 2452 | 0.070 |
Why?
|
| Analysis of Variance | 4 | 2004 | 6862 | 0.070 |
Why?
|
| History, 20th Century | 2 | 2010 | 2860 | 0.070 |
Why?
|
| Markov Chains | 2 | 2017 | 950 | 0.070 |
Why?
|
| Research Subjects | 1 | 2004 | 198 | 0.070 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 91 | 0.070 |
Why?
|
| Hypertension | 2 | 1998 | 7203 | 0.070 |
Why?
|
| Motor Skills | 1 | 2006 | 515 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 1417 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 2 | 2013 | 680 | 0.060 |
Why?
|
| Incidence | 3 | 2016 | 18412 | 0.060 |
Why?
|
| Nervous System | 1 | 2006 | 578 | 0.060 |
Why?
|
| Myocardial Infarction | 3 | 2005 | 10779 | 0.060 |
Why?
|
| Pentamidine | 1 | 2000 | 46 | 0.060 |
Why?
|
| Public Health Practice | 1 | 2003 | 201 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2016 | 6585 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3731 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 1998 | 4718 | 0.060 |
Why?
|
| Air Pollutants, Occupational | 3 | 1989 | 427 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2017 | 20694 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2013 | 2921 | 0.060 |
Why?
|
| Carbon Compounds, Inorganic | 2 | 1989 | 11 | 0.060 |
Why?
|
| Silicon Compounds | 2 | 1989 | 13 | 0.060 |
Why?
|
| Veterans | 1 | 2010 | 1496 | 0.060 |
Why?
|
| Heart | 1 | 1993 | 3961 | 0.060 |
Why?
|
| Silicon | 2 | 1989 | 131 | 0.050 |
Why?
|
| Penetrance | 1 | 2000 | 300 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2014 | 21460 | 0.050 |
Why?
|
| Prenatal Care | 1 | 2006 | 877 | 0.050 |
Why?
|
| Public Health | 1 | 1991 | 1893 | 0.050 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2006 | 1051 | 0.050 |
Why?
|
| Graft vs Leukemia Effect | 1 | 1999 | 97 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 15391 | 0.050 |
Why?
|
| Follow-Up Studies | 7 | 2016 | 36866 | 0.050 |
Why?
|
| Isoniazid | 1 | 1999 | 208 | 0.050 |
Why?
|
| Aerosols | 1 | 2000 | 594 | 0.050 |
Why?
|
| Risperidone | 1 | 2001 | 368 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2010 | 1703 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2010 | 2244 | 0.050 |
Why?
|
| Boston | 2 | 2007 | 8840 | 0.050 |
Why?
|
| Pregnancy | 4 | 2014 | 22620 | 0.050 |
Why?
|
| Models, Structural | 1 | 1998 | 371 | 0.050 |
Why?
|
| Vitamins | 1 | 2006 | 1135 | 0.050 |
Why?
|
| Health Surveys | 1 | 2008 | 3808 | 0.050 |
Why?
|
| Disease Progression | 4 | 2011 | 11862 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2006 | 1237 | 0.050 |
Why?
|
| Respiration Disorders | 2 | 1989 | 308 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2018 | 53353 | 0.050 |
Why?
|
| Child | 3 | 2018 | 61754 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2004 | 2619 | 0.040 |
Why?
|
| Homozygote | 1 | 2001 | 1771 | 0.040 |
Why?
|
| Systems Analysis | 1 | 2017 | 118 | 0.040 |
Why?
|
| Aged | 11 | 2018 | 143921 | 0.040 |
Why?
|
| Family | 1 | 2007 | 2886 | 0.040 |
Why?
|
| Bisexuality | 1 | 1998 | 230 | 0.040 |
Why?
|
| Influenza in Birds | 2 | 2006 | 61 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 1691 | 0.040 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2006 | 1532 | 0.040 |
Why?
|
| Carbon | 2 | 1989 | 619 | 0.040 |
Why?
|
| Birds | 2 | 2006 | 147 | 0.040 |
Why?
|
| Zimbabwe | 1 | 2015 | 93 | 0.040 |
Why?
|
| Exostoses | 1 | 1975 | 28 | 0.040 |
Why?
|
| Proteins | 1 | 2012 | 6205 | 0.040 |
Why?
|
| Methotrexate | 1 | 2002 | 1571 | 0.040 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2006 | 104 | 0.040 |
Why?
|
| Research | 1 | 2004 | 1968 | 0.040 |
Why?
|
| Prevalence | 2 | 2008 | 13229 | 0.040 |
Why?
|
| Neuropsychological Tests | 2 | 2006 | 6423 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2018 | 13741 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2018 | 600 | 0.040 |
Why?
|
| Heterozygote | 1 | 2001 | 2607 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1999 | 625 | 0.040 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1975 | 130 | 0.040 |
Why?
|
| Massachusetts | 2 | 2016 | 7977 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 6863 | 0.040 |
Why?
|
| Age Factors | 2 | 2018 | 17992 | 0.040 |
Why?
|
| Phenotype | 2 | 2001 | 14462 | 0.040 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 435 | 0.040 |
Why?
|
| Developing Countries | 1 | 2006 | 2444 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2000 | 888 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2006 | 2603 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2000 | 3614 | 0.040 |
Why?
|
| Lung Neoplasms | 3 | 1998 | 10451 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 2590 | 0.030 |
Why?
|
| Adolescent | 5 | 2017 | 76014 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2012 | 5763 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 2002 | 1190 | 0.030 |
Why?
|
| Tanzania | 2 | 2006 | 958 | 0.030 |
Why?
|
| Mammography | 1 | 2004 | 2337 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 667 | 0.030 |
Why?
|
| El Salvador | 1 | 1991 | 35 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 2001 | 1191 | 0.030 |
Why?
|
| Birth Weight | 2 | 1999 | 1773 | 0.030 |
Why?
|
| Uganda | 1 | 2015 | 862 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1997 | 592 | 0.030 |
Why?
|
| Toxoplasmosis | 1 | 1991 | 94 | 0.030 |
Why?
|
| Wisconsin | 1 | 2010 | 121 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2007 | 4577 | 0.030 |
Why?
|
| Registries | 1 | 2005 | 6677 | 0.030 |
Why?
|
| Prognosis | 2 | 2008 | 25541 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1999 | 2866 | 0.030 |
Why?
|
| Life Style | 2 | 2013 | 3256 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 903 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2010 | 144 | 0.030 |
Why?
|
| Sulfur Dioxide | 1 | 1989 | 179 | 0.030 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1988 | 50 | 0.030 |
Why?
|
| Asbestos | 1 | 1991 | 231 | 0.030 |
Why?
|
| Rwanda | 1 | 2011 | 561 | 0.030 |
Why?
|
| Alleles | 1 | 2000 | 6760 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 1993 | 1236 | 0.030 |
Why?
|
| Psychotic Disorders | 1 | 2001 | 2307 | 0.030 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 3593 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 2289 | 0.020 |
Why?
|
| Child, Preschool | 4 | 2018 | 37274 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1989 | 667 | 0.020 |
Why?
|
| Accidents, Home | 1 | 1988 | 76 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2010 | 299 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1999 | 4514 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2002 | 3233 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 1992 | 743 | 0.020 |
Why?
|
| Depression | 1 | 2005 | 5638 | 0.020 |
Why?
|
| Eating | 1 | 2013 | 1213 | 0.020 |
Why?
|
| Silicosis | 1 | 1986 | 46 | 0.020 |
Why?
|
| Containment of Biohazards | 1 | 2006 | 31 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2000 | 3859 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1578 | 0.020 |
Why?
|
| Antipsychotic Agents | 2 | 2015 | 2948 | 0.020 |
Why?
|
| Maximal Expiratory Flow Rate | 1 | 1984 | 48 | 0.020 |
Why?
|
| Animals | 5 | 2013 | 165878 | 0.020 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 1984 | 79 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 1991 | 707 | 0.020 |
Why?
|
| Health Promotion | 1 | 2017 | 1945 | 0.020 |
Why?
|
| Respiratory Function Tests | 2 | 1986 | 1566 | 0.020 |
Why?
|
| Overweight | 1 | 2016 | 1859 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1991 | 834 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 1319 | 0.020 |
Why?
|
| Young Adult | 3 | 2017 | 47226 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1996 | 2203 | 0.020 |
Why?
|
| Maximum Allowable Concentration | 1 | 1983 | 70 | 0.020 |
Why?
|
| Communicable Disease Control | 2 | 2004 | 485 | 0.020 |
Why?
|
| Hong Kong | 1 | 2003 | 132 | 0.020 |
Why?
|
| Quarantine | 1 | 2003 | 51 | 0.020 |
Why?
|
| Patient Isolation | 1 | 2003 | 83 | 0.020 |
Why?
|
| Morbidity | 1 | 1988 | 1411 | 0.020 |
Why?
|
| Infant | 3 | 2018 | 30409 | 0.020 |
Why?
|
| Cities | 1 | 2004 | 391 | 0.020 |
Why?
|
| Singapore | 1 | 2003 | 214 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 6857 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 11521 | 0.020 |
Why?
|
| Genotype | 1 | 1998 | 12558 | 0.020 |
Why?
|
| Contact Tracing | 1 | 2003 | 158 | 0.020 |
Why?
|
| Longevity | 1 | 1988 | 851 | 0.020 |
Why?
|
| Spirometry | 1 | 1984 | 804 | 0.020 |
Why?
|
| Malaria | 1 | 1990 | 978 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 1996 | 12664 | 0.020 |
Why?
|
| Lead Poisoning | 1 | 1983 | 293 | 0.020 |
Why?
|
| Disaster Planning | 1 | 2006 | 523 | 0.010 |
Why?
|
| Tuberculosis | 1 | 2011 | 1485 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 53121 | 0.010 |
Why?
|
| Lung | 2 | 1989 | 8324 | 0.010 |
Why?
|
| Physicians | 1 | 2015 | 3516 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 4390 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6591 | 0.010 |
Why?
|
| Lead | 1 | 1983 | 724 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1985 | 1228 | 0.010 |
Why?
|
| Health Behavior | 1 | 2009 | 2359 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 1853 | 0.010 |
Why?
|
| Burns | 1 | 1988 | 1733 | 0.010 |
Why?
|
| Placebos | 1 | 2001 | 1708 | 0.010 |
Why?
|
| Heel | 1 | 1975 | 35 | 0.010 |
Why?
|
| Elbow | 1 | 1975 | 123 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 8561 | 0.010 |
Why?
|
| Wrist | 1 | 1975 | 158 | 0.010 |
Why?
|
| Knee | 1 | 1975 | 223 | 0.010 |
Why?
|
| Humerus | 1 | 1975 | 189 | 0.010 |
Why?
|
| Health Policy | 1 | 2006 | 2403 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 2403 | 0.010 |
Why?
|
| Pelvic Bones | 1 | 1975 | 250 | 0.010 |
Why?
|
| Forearm | 1 | 1975 | 395 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 1996 | 758 | 0.010 |
Why?
|
| Quality of Life | 1 | 1991 | 8574 | 0.010 |
Why?
|
| Occupations | 2 | 1984 | 485 | 0.010 |
Why?
|
| Leukemia | 1 | 1999 | 1412 | 0.010 |
Why?
|
| Foot | 1 | 1975 | 532 | 0.010 |
Why?
|
| Hand | 1 | 1975 | 733 | 0.010 |
Why?
|
| Thoracic Vertebrae | 1 | 1975 | 574 | 0.010 |
Why?
|
| Age of Onset | 1 | 1996 | 3078 | 0.010 |
Why?
|
| Aging | 2 | 1986 | 7783 | 0.010 |
Why?
|
| Immunization, Secondary | 1 | 1990 | 245 | 0.010 |
Why?
|
| Leg | 1 | 1975 | 1201 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1990 | 186 | 0.010 |
Why?
|
| Syndrome | 1 | 1975 | 3013 | 0.010 |
Why?
|
| Femur | 1 | 1975 | 1220 | 0.010 |
Why?
|
| Cervical Vertebrae | 1 | 1975 | 822 | 0.010 |
Why?
|
| Dust | 1 | 1989 | 436 | 0.010 |
Why?
|
| Vital Capacity | 1 | 1989 | 854 | 0.010 |
Why?
|
| Brazil | 1 | 1990 | 1182 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1975 | 1511 | 0.010 |
Why?
|
| National Health Programs | 1 | 1990 | 448 | 0.010 |
Why?
|
| Immunity | 1 | 1990 | 600 | 0.010 |
Why?
|
| Radiography | 1 | 1975 | 7010 | 0.000 |
Why?
|
| Employment | 1 | 1989 | 952 | 0.000 |
Why?
|
| Connecticut | 1 | 1983 | 344 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1983 | 313 | 0.000 |
Why?
|
| Blood Cell Count | 1 | 1983 | 397 | 0.000 |
Why?
|
| Hemolysis | 1 | 1983 | 376 | 0.000 |
Why?
|
| Hematocrit | 1 | 1983 | 641 | 0.000 |
Why?
|
| Program Evaluation | 1 | 1990 | 2445 | 0.000 |
Why?
|
| Anemia | 1 | 1983 | 1280 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1983 | 8317 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 1986 | 17567 | 0.000 |
Why?
|
| Neoplasms | 1 | 1985 | 16399 | 0.000 |
Why?
|